» Articles » PMID: 36578669

Prevalence and Characteristics of Sleep Apnea in Intensive Care Unit Survivors After SARS-CoV-2 Pneumonia

Abstract

Background: Sleep apnea (SA) was reported as possibly exacerbating symptoms of COVID-19, a disease induced by SARS-CoV-2 virus. The same comorbidities are common with both pathologies. This study aimed to estimate the prevalence, characteristics of SA and variation in AHI three months after severe COVID-19 requiring intensive care unit (ICU) admission.

Methods: A prospective cohort of patients admitted to ICU for severe COVID-19 underwent an overnight home polygraphy 3 months after onset of symptoms, as part of a comprehensive follow-up program (pulmonary function tests, 6-minute walk tests and chest CT-scan). Patients with an apnea hypopnea index (AHI) ≥5 were considered as having SA. We performed a comparative descriptive analysis of 2 subgroups according to the existence, severity of SA and indication for effective SA treatment: patients with absent or mild SA (AHI <15) vs patients with moderate to severe SA (AHI ≥15).

Results: Among 68 patients included, 62 (91%) had known comorbidities (34 hypertension, 21 obesity, 20 dyslipidemia, 16 type 2 diabetes). It has been observed a preexisting SA for 13 patients (19.1%). At 3 months, 62 patients (91%) had SA with 85.5% of obstructive events. Twenty-four patients had no or a mild SA (AHI <15) and 44 had moderate to severe SA (AHI ≥15). Ischemic heart disease exclusively affected the moderate to severe SA group. Except for thoracic CT-scan which revealed less honeycomb lesions, COVID-19 symptoms were more severe in the group with moderate to severe SA, requiring a longer curarization, more prone position sessions and more frequent tracheotomy.

Conclusion: SA involved 91% of patients in our population at 3 months of severe COVID-19 and was mainly obstructive type. Although SA might be a risk factor as well as consequences of ICU care in severe COVID-19 infection, our results underline the importance of sleep explorations after an ICU stay for this disease.

Citing Articles

Clinical Approach to Patients with COVID-19 and Unrecognized Obstructive Sleep Apnea.

Curic M, Marinelli F, Prica V, Pavlovic M, Barkovic I Clin Pract. 2024; 14(2):629-641.

PMID: 38666808 PMC: 11049666. DOI: 10.3390/clinpract14020050.

References
1.
Maas M, Kim M, Malkani R, Abbott S, Zee P . Obstructive Sleep Apnea and Risk of COVID-19 Infection, Hospitalization and Respiratory Failure. Sleep Breath. 2020; 25(2):1155-1157. PMC: 7521948. DOI: 10.1007/s11325-020-02203-0. View

2.
Jennum , Sjol . Epidemiology of snoring and obstructive sleep apnoea in a Danish population, age 30-60. J Sleep Res. 1992; 1(4):240-244. DOI: 10.1111/j.1365-2869.1992.tb00045.x. View

3.
Pinto J, Ribeiro D, Cavallini A, Duarte C, Freitas G . Comorbidities Associated with Obstructive Sleep Apnea: a Retrospective Study. Int Arch Otorhinolaryngol. 2016; 20(2):145-50. PMC: 4835326. DOI: 10.1055/s-0036-1579546. View

4.
George P, Wells A, Gisli Jenkins R . Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020; 8(8):807-815. PMC: 7228727. DOI: 10.1016/S2213-2600(20)30225-3. View

5.
Redline S, Kapur V, Sanders M, Quan S, Gottlieb D, Rapoport D . Effects of varying approaches for identifying respiratory disturbances on sleep apnea assessment. Am J Respir Crit Care Med. 2000; 161(2 Pt 1):369-74. DOI: 10.1164/ajrccm.161.2.9904031. View